ReviewOphthalmology2015
Pathophysiology and mechanisms of severe retinopathy of prematurity.
Review in Ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
195 citing papers in PubMed, 3 syntheses or guidelines pooled it, 344 citations in OpenAlex.
- Analgesia for retinopathy of prematurity screening: A systematic review.Pain practice : the official journal of World Institute of Pain · 2022Pooled it
- Chorioamnionitis as a risk factor for retinopathy of prematurity: An updated systematic review and meta-analysis.PloS one · 2018Pooled it
- Probiotic supplementation in preterm infants does not affect the risk of retinopathy of prematurity: a meta-analysis of randomized controlled trials.Scientific reports · 2017Pooled it
- Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.Eye (London, England) · 2024Trial
- Evaluation of computer-based retinopathy of prematurity (ROP) education for ophthalmology residents: a randomized, controlled, multicenter study.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2019Trial
- Semi-automated quantification of total and avascular retinal area in the rat model of oxygen-induced retinopathy.Angiogenesis · 2026Article
- Impact of image enhancement on grading agreement of plus disease features in retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Relationship Between Retinopathy of Prematurity and Anemia and Red Blood Cell Transfusions in Very Premature/Very-Low-Birth-Weight Neonates.Diagnostics (Basel, Switzerland) · 2026Article
- Comparison of Success Rates Between Laser Photocoagulation and Intravitreal Anti-Vascular Endothelial Growth Factor Injection for the Treatment of Retinopathy of Prematurity in a Tertiary Referral Center: An 11-Year Survey.Journal of clinical practice and research · 2026Article
- Oxygen therapy-related risk factors for aggressive retinopathy of prematurity in low-risk preterm neonates.Pediatric research · 2026Article
- Sigma 1 Receptor Activation Coordinates Metabolic Stress Responses to Protect Retinal Vasculature in Ischemic Retinopathy.Investigative ophthalmology & visual science · 2026Article
- Bemarituzumab Suppresses Choroidal Neovascularization in Mice by Downregulating Melanoma Cell Adhesion Molecule and Yes-Associated Protein 1.ACS pharmacology & translational science · 2026Article
- Low serum sphingosine-1-phospate and its chaperone ApoM associate with retinopathy of prematurity.Journal of lipid research · 2026Article
- Coviretinopathy: COVID-19-induced VEGF-dependent retinopathy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Development of a Disposable Chemiresistive Biochip for Tear-Based Retinopathy of Prematurity Diagnosis: Early Screening and Risk Prediction.IEEE sensors journal · 2026Article
- Ocular surface inflammatory cytokines as a biomarker for retinopathy of prematurity.Eye (London, England) · 2026Article
- Article
- Review
- Swept-source optical coherence tomography analysis of retinal and choroidal structures in school-aged children after laser photocoagulation for type 1 retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Inhibition of pathological angiogenesis in oxygen-induced retinopathy by arginine depletion with ADI-PEG20.Experimental eye research · 2026Article
135 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Retinopathy of prematurity (ROP) affects only premature infants, but as premature births increase in many areas of the world, ROP has become a leading cause of childhood blindness. Blindness can occur from aberrant developmental angiogenesis that leads to fibrovascular retinal detachment. To treat severe ROP, it is important to study normal developmental angiogenesis and the stresses that activate pathologic signaling events and aberrant angiogenesis in ROP. Vascular endothelial growth factor (VEGF) signaling is important in both physiologic and pathologic developmental angiogenesis. Based on studies in animal models of oxygen-induced retinopathy (OIR), exogenous factors such as oxygen levels, oxidative stress, inflammation, and nutritional capacity have been linked to severe ROP through dysregulated signaling pathways involving hypoxia-inducible factors and angiogenic factors like VEGF, oxidative species, and neuroprotective growth factors to cause phases of ROP. This translational science review focuses on studies performed in animal models of OIR representative of human ROP and highlights several areas: mechanisms for aberrant growth of blood vessels into the vitreous rather than into the retina through over-activation of VEGF receptor 2 signaling, the importance of targeting different cells in the retina to inhibit aberrant angiogenesis and promote physiologic retinal vascular development, toxicity from broad and targeted inhibition of VEGF bioactivity, and the role of VEGF in neuroprotection in retinal development. Several future translational treatments are discussed, including considerations for targeted inhibition of VEGF signaling instead of broad intravitreal anti-VEGF treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.